Palvella Therapeutics
IPOHomepage
Public · Wayne, United States · Founded 2015 · $109.7M raised
- Headquarters
- Wayne, Pennsylvania
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- palvellatx.com
- Total Funding
- $109.7M
- Last Round
- $45.0M Series DJan 2023
- Rounds
- 4
- Type
- Public
About
Palvella Therapeutics is a clinical-stage biopharmaceutical company specializing in developing medicines for patients with rare dermatological diseases with no approved therapies. Its QTORIN platform delivers topical rapamycin-based treatments, with its lead candidate in Phase 3 trials for microcystic lymphatic malformations and Phase 2 for cutaneous venous malformations.
Summary
Palvella Therapeutics is a Biotech company based in Wayne, United States, founded in 2015. It has raised $109.7M in total across 4 rounds, most recently a $45.0M Series D round in Jan 2023.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...